Chi Li

Chi is Senior Vice President and Chief Regulatory Officer of Editas Medicine He joined Editas Medicine in June 2021 and is responsible for leading Editas Medicine's regulatory affairs strategy and activities related to its drug development programs.

Chi brings to Editas more than 20 years of experience in drug development in the pharmaceutical and biotechnology industry. He played an important and strategic role in the development, submission, and approval of several drugs and biologics across a number of therapeutic areas, globally and in the United States. Before joining Editas, Chi served as Chief Regulatory Officer at Celularity, and as Vice President, Regulatory Affairs at both Allergan and Bayer.